Aarti Pharmalabs Ltd
AARTIPHARMAarti Pharmalabs Ltd
AARTIPHARMPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
23.88 | 2.98 | 0.39% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
52.80 | 5.98 | 0.57% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
Investor Presentation
View olderPeers
Compare with peersDivi's Laboratories Ltd
Syngene International Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Brooks Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | |||||
---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 0.00 | 0.00 | 1,202.45 | 1,947.61 | 1,835.50 | |||||
Raw Materials | 0.00 | 0.00 | 686.72 | 1,141.17 | 1,483.39 | |||||
Power & Fuel Cost | 0.00 | 44.14 | 75.10 | |||||||
Employee Cost | 0.00 | 85.20 | 129.69 | |||||||
Selling & Administrative Expenses | 0.02 | 27.35 | 63.98 | |||||||
Operating & Other expenses | 0.00 | 149.58 | 193.31 | |||||||
EBITDA | -0.02 | 0.00 | 209.46 | 344.36 | 352.11 | |||||
Depreciation/Amortization | 0.00 | 0.00 | 42.12 | 62.54 | 70.06 | |||||
PBIT | -0.02 | 0.00 | 167.34 | 281.82 | 282.05 | |||||
Interest & Other Items | 0.00 | 0.00 | 11.96 | 21.05 | 18.48 | |||||
PBT | -0.02 | 0.00 | 155.38 | 260.77 | 263.57 | |||||
Taxes & Other Items | 0.00 | 0.00 | 33.13 | 67.28 | 69.05 | |||||
Net Income | -0.02 | 0.00 | 122.25 | 193.49 | 194.52 | |||||
EPS | -0.80 | 0.00 | 4,890.00 | 42.58 | 21.46 | |||||
DPS | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 | |||||
Payout ratio | 0.00 | — | 0.00 | 0.05 | 0.00 |
Company Updates
Peers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Aarti Pharmalabs Ltd | 24.01 | 2.98 | 0.39% |
Divi's Laboratories Ltd | 57.72 | 8.24 | 0.76% |
Syngene International Ltd | 54.08 | 7.62 | 0.18% |
Dishman Carbogen Amcis Ltd | -121.09 | 0.62 | — |
Price Comparison
Compare AARTIPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Aarti Pharmalabs Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8198% | Percentage of the fund’s portfolio invested in the stock 0.19% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/89 (+4) |
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5611% | Percentage of the fund’s portfolio invested in the stock 0.69% | Change in the portfolio weight of the stock over the last 3 months 0.69% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/59 (-13) |
HDFC MULTI CAP FUND - DIRECT PLAN - GROWTH OPTION Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4015% | Percentage of the fund’s portfolio invested in the stock 0.15% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 168/195 (-16) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateFeb 16, 2024
Dividend/Share
₹2.00
Ex DateEx Date
Feb 16, 2024
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant